Grin Therapeutics Inc.

Clinical trials supported by the company include studies in focal cortical dysplasia (FCD) type II and tuberous sclerosis complex (TSC), both associated with refractory seizure burden and broader neurological impairment.

• Focal cortical dysplasia (FCD) type II
• Tuberous sclerosis complex (TSC)
• Seizure frequency

These programs reflect a therapeutic interest in seizure-related outcomes and associated neurobehavioral features across rare epilepsy syndromes.

The sponsor’s clinical portfolio includes pediatric studies across rare neurological conditions, with emphasis on long-term tolerability and treatment response in children and adolescents.

• Pediatric participants
• Long-term safety
• Neurological symptom control

Research sites span multiple countries, supporting the evaluation of therapies for uncommon childhood-onset disorders with complex neurological presentations.

In addition to seizure-related endpoints, the company studies non-seizure behavior features and other functional symptoms that accompany rare neurogenetic disorders.

• Non-seizure behavior features
• Behavioral symptoms
• Functional neurological outcomes

This area of interest links neurological disease management with broader symptom domains that affect daily functioning in affected individuals.

Grin Therapeutics Inc. also investigates pharmacokinetics, plasma exposure, and overall safety and tolerability across its neurological programs.

• Pharmacokinetics
• Plasma exposure
• Safety and tolerability

These areas support the clinical development of therapies intended for chronic use in rare central nervous system disorders.